Skip to main content

Now Accepting New Patients

15–20%
avg body weight loss
in clinical trials

Weight Management

Your weight isn’t a willpower problem. It’s biology.

Medically-supervised treatment with the latest GLP-1 medications, prescribed by our GPs and delivered to your door.

CQC RegulatedGP-Led TreatmentUKAS Labs

Weight gain has many causes.
None of them are your fault.

Genetics

Over 200 genes influence body weight and fat distribution

Hormones

Appetite hormones can override your best intentions

Metabolism

Your body actively resists weight loss after dieting

Evidence-Based

The science behind lasting results

Mounjaro

tirzepatide

Dual GIP + GLP-1 receptor agonist

Up to 22.5% body weight loss in trials1

  • Reduces appetite and food cravings
  • Improves blood sugar regulation
  • Once-weekly self-injection
  • Gradual dose escalation over 20 weeks
  • Most common side effects are mild GI symptoms

Wegovy

semaglutide

GLP-1 receptor agonist

Up to 15% body weight loss in trials2

  • Signals fullness to the brain
  • Shown cardiovascular benefits
  • Once-weekly self-injection
  • Dose titration over 16 weeks
  • Well-established safety profile since 2021

Your Journey

Three steps. That’s it.

1

Online consultation

15 minutes, from home. Share your history and goals.

2

GP prescribes

Reviewed by our doctors. Bloods taken at our clinic if needed.

3

Medication delivered

Monthly, to your door. Ongoing GP support included.

Results

What to expect

Month 1

Appetite changes

Reduced cravings, feeling fuller sooner. Typical loss: 2\u20135% body weight.

Months 2\u20133

Steady progress

Consistent weight loss as dosage optimises. Typical loss: 5\u201310% total.

Months 6\u201312

New baseline

Significant transformation. Typical loss: 15\u201320% total body weight.

Investment

Transparent pricing. No hidden fees.

Initial consultation60 minutes — includes baseline blood tests
£250
Mounjarotirzepatide
From£280/month
Wegovysemaglutide
From£224/month
Follow-up consultationsGP review every 2–3 months + ongoing blood monitoring — bundled in monthly medication price
Included

Monthly price includes medication, GP consultations, and blood monitoring. Dose-specific pricing discussed at your consultation.

Am I suitable?

  • BMI of 30 or above
  • BMI of 27+ with a weight-related condition (e.g. type 2 diabetes, high blood pressure, sleep apnoea)
  • Age 18 or over
  • Previous attempts at lifestyle changes alone haven’t worked

May not be suitable if:

Pregnant or planning pregnancy · Personal or family history of medullary thyroid carcinoma or MEN2 syndrome · Type 1 diabetes · History of pancreatitis · Severe gastrointestinal disease. Our GPs will assess your full medical history during consultation.

Common questions

Both Mounjaro and Wegovy are MHRA-approved and backed by large-scale clinical trials. Side effects are typically mild and GI-related (nausea, reduced appetite) and tend to subside as your body adjusts. Your GP monitors you throughout.
Clinical trials show 15–22.5% average body weight loss over 12–18 months. Individual results vary based on starting weight, medication, and lifestyle factors. Most patients notice appetite changes within the first 2–4 weeks.
A 15-minute online or in-person appointment with one of our GPs. We review your medical history, discuss your goals, and determine which medication is right for you. Blood tests may be arranged at our Balsall Common clinic.
Research shows some weight regain can occur after stopping. That’s why our programme includes lifestyle guidance alongside medication. Your GP will work with you on a sustainable long-term plan, including a gradual step-down if appropriate.
Yes, our GPs can help you switch if one medication isn’t suiting you. This is managed during your follow-up consultations, which are included in your programme.
Consultations can be done online. You may need to visit our Balsall Common clinic for blood tests, but medication is delivered directly to your home each month.

Ready to start?

1 SURMOUNT-1 trial: Jastreboff AM, et al. N Engl J Med. 2022;387:205-216. Tirzepatide for obesity.
2 STEP 1 trial: Wilding JPH, et al. N Engl J Med. 2021;384:989-1002. Semaglutide for obesity.
Individual results may vary. All treatments prescribed by GMC-registered GPs.

Check your eligibility